Quality of Life and Psychological Vulnerability in Patients With RH+ Metastatic Breast Cancer (EPOCA)
Metastatic Breast Cancer, Positive Hormonal Receptors
About this trial
This is an interventional supportive care trial for Metastatic Breast Cancer focused on measuring Quality of Life, Psychological vulnerability
Eligibility Criteria
Inclusion Criteria:
- Histologically confirmed diagnosis of invasive breast cancer (=infiltrant). NB: Mixed histologies are allowed
- Adult women (≥ 18 years),
- Positive hormonal receptors (Estrogen receptors and/or Progesterone receptors ≥10%) and HER2 negative
- Patient in need of a 1st metastatic treatment line NB: Patients may have received prior treatment for their cancer, but not for their metastatic disease.
- Performance status ≤ 1 (world health organization)
- Patients affiliated to a Social Security,
- Obtaining the patient's signed written consent
Exclusion Criteria:
- Patient with non-metastatic breast cancer,
- man
- Negative hormonal receptors or HER2 positive
- Psychiatric history with specialist diagnosis
- Pregnant or nursing patient
- Patients who cannot be followed regularly for psychological reasons (cognitive problems preventing completion of questionnaires), or because of geographical remoteness.
- Person deprived of liberty or adult under guardianship
Sites / Locations
- Ico Angers
- Ico Nantes
Arms of the Study
Arm 1
Experimental
quality of life in metastatic BC
Patients benefit from a longitudinal follow-up determined according to the treatments. Each type of treatment has its own schedule based on medical consultation times. At each change of treatment, from chemotherapy to hormone therapy or vice versa, the assessment times are determined according to the nature of the treatment. The rhythm of the evaluation visits will therefore be defined by the doctor, according to the habits of the centre. The evaluation times used to collect the questionnaires (QLQ-C30, BR23, PDS, STAI, BDI II).